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Summary: This article provides a comprehensive review of currently available treatment 
options for infections due to carbapenem-resistant enterobacteriaceae (CRE). 
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Abstract. 
Antimicrobial resistance in Gram-negative bacteria is an emerging and serious global public 
health threat. Carbapenems have been used as the “last-line” treatment for infections caused by 
resistant enterobacteriaceae, including those producing extended spectrum ß-lactamases.  
However, enterobacteriaceae that produce carbapenemases, which are enzymes that 
deactivate carbapenems and most other ß-lactam antibiotics, have emerged and are 
increasingly being reported worldwide.  Despite increasing burden, the most optimal treatment 
for carbapenem-resistant enterobacteriaceae (CRE) infections is largely unknown.  For the few 
remaining available treatment options, there is limited efficacy data to support their role in 
therapy.  Nevertheless, current treatment options include the use of older agents, such as 
polymyxins, fosfomycin, and aminoglycosides, which have been rarely used due to efficacy 
and/or toxicity concerns.  Optimization of dosing regimens and combination therapy are 
additional treatment strategies being explored.  CRE infections are associated with poor 
outcomes and high mortality.  Continued research is critically needed to determine the most 
appropriate treatment.  
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Introduction. 
 Antimicrobial resistance is globally recognized as one of the greatest threats to public 
health.  Of particular concern, are infections caused by resistant Gram-negative bacilli, which 
are increasingly being reported worldwide. The escalating burden of Gram-negative 
antimicrobial resistance is largely due to ß-lactamases, which are enzymes that bind and 
deactivate ß-lactam antibiotics, rendering them ineffective.  For years, carbapenems have been 
used successfully to treat infections due to resistant enterobacteriaceae, such as Escherichia 
Coli and Klebsiella pneumoniae, including those producing extended spectrum ß-lactamases 
(ESBLs; a subset of ß-lactamase enzymes which confer broad resistance to penicillins, 
cephalosporins, and the monobactam aztreonam).  
However, recently enterobacteriaceae producing carbapenemases (known as 
carbapenem-resistant enterobacteriaceae [CRE]) have emerged, which confer broad resistance 
to most ß-lactam antibiotics including “last-line” carbapenems.  Carbapenem resistance can 
also be conferred when porin deficiencies, which allow decreased entry of the ß-lactam into the 
cell membrane, are combined with ESBLs.[1]  The prevalence of CRE infections has incresed 
over the last decade, especially in healthcare settings and CRE have been recognized by the 
United States Centers for Disease Control and Prevention as an urgent public health threat.[2, 
3]  The Ceners for Disease Control and Prevention estimates that more than 9,000 healthcare-
assocaited infections are caused by the two most common type of CRE, carbapenem-resistant 
Klebsiella species and carbapenem-resistant Escherichia species, each year in the United 
States.[3]  CRE can cause a number of serious infection types (such as intra-abdominal 
infections, pneumonia, urinary tract infections, and device-associated infections) or 
asymptomatic colonization.[4-6]  Each year approximtaley 600 deaths result from CRE 
infections. [3]  CRE mortality rates are high and range from 18% to 60% depending on 
therapy.[7]  This may be due to delayed time to active therapy, pharmacologic limitations of 
available treatment options, and that patients with CRE infections tend to be critically ill.   
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At this time there are a limited selection of treatment options for CRE infections. 
Clinicians have been forced to re-evaluate the use of agents, which have been historically rarely 
used due to efficacy and/or toxicity concerns, such as polymyxins, fosfomycin, and 
aminoglycosides.  Additional CRE treatment strategies include optimization of dosing regimens 
and combination therapy.  This review will focus on the current treatment options for CRE 
infections.  
 
Overview of Carbapenem-resistant Enterobacteriaceae (CRE)Treatment. 
There are numerous different types of carbapenemase enzymes, each conferring 
varying spectrums of resistance.  An overview of the carbapenemase enzyme types with the 
greatest clinical importance can be found in Table 1.  In general, the presence of a 
carbapenemase confers broad resistance to most ß-lactam antibiotics including penicillins, 
cephalosporins, and the monobactam aztreonam (excluding MBLs and OXAs).[1]  In vitro 
activity of carbapenems in the setting of one of these enzymes is variable, and the exact role of 
carbapenems in infectious due to these organisms is controversial.  To further complicate 
treatment, CRE often exhibit resistance to structurally unrelated antimicrobial classes such as 
aminoglycosides and fluoroquinolones.[8]  However, aminoglycoside susceptibility can vary as a 
function of KPC strain type and co-existing aminoglycoside modifying enzymes, which are not 
tested in a traditional clinical laboratory.  The emergence of resistance during therapy is another 
emerging concern.[9, 10]  
Despite their increasing burden, the most optimal treatment for CRE infections is largely 
unknown.  At this time, there is no published data from randomized controlled trials assessing 
antimicrobial treatment options for CRE infections.  While important, in the United States at this 
time there may not be a sufficient amount of patients with serious CRE infections to conduct 
such a trial.  Therefore, much of the existing evidence is from reviews of case reports, case 
series and small retrospective studies, which have a number of inherent limitations.[11, 12]  A 
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potential CRE treatment algorithm and overviews of current treatment options can be found in 
Tables 2 and 3, respectively. 
Carbapenems. 
 Pharmacokinetic data suggests that T>MIC targets can be achieved using high-dose 
prolonged-infusion carbapenems when carbapenem MICs are relatively low (<4µg/ml) or even 
moderately elevated (8-16µg/ml).[13-17]   In a pharmacokinetic study of ten critically ill patients, 
high-dose meropenem (6000mg/day) administered by prolonged (over 4 hours)/continuous 
infusion had a high probability of target attainment (PTA) up to an MIC of 8-16µg/ml.[13]  In 
another study, the PTA for an MIC of 4µg/ml increased with prolonged-infusion (over 3 hours) 
as compared to traditional-infusion (over 30 minutes); the PTA for prolonged-infusions were 
100% (2000mg q8h) and 93% (1000mg q8h) as compared to 69% for traditional-infusion 
(1000mg q8h).[14]  At an MIC of 8µg/ml, only high-dose prolonged-infusion meropenem had a 
high PTA(85%).  
 While pharmacokinetic data appears favorable, there is only limited clinical data 
assessing the efficacy of carbapenem monotherapy in the treatment of CRE infections.  In a 
study that compiled data from eight clinical trials, in 44 patients treated with carbapenem 
monotherapy for infections due to carbapenemase-producing K. pneumoniae, treatment efficacy 
varied based on MIC.[17]  The efficacy ranged from 69% (MIC <4µg/ml), 60% (MIC 8µg/ml), to 
only 29% (MIC >8µg/ml).  Treatment efficacy when the MIC was <4µg/ml was similar to that 
observed in 22 patients with non-carbapenemase-producing K. pneumoniae infections (73%). 
The lowest mortality rate was observed in patients who received carbapenem-containing-
combination treatment (MIC <4µg/ml).  The mortality rate was lower for patients who received 
carbapenem-containing as compared to non-carbapenem regimens (12%[3/26] vs. 
41%[46/112]; P=0.006).[17]  In a recent review, the mortality rate associated with carbapenem 
monotherapy was unacceptably high (40.1%).[12]  For patients with serious infections and/or 
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who are critically ill adding another active agent may increase the probability of clinical 
response. 
 Additionally, several retrospective studies have observed lower rates of mortality with 
carbapenem-based combination therapy as compared to non-carbapenem combination 
therapy.[17-20]  The efficacy of carbapenem combination therapy also appears to be MIC 
dependent.  In a large multi-center study where high-dose prolonged-infusion meropenem was 
used (2000mg administered over >3 hours q8h) mortality rates stratified by MIC were as 
follows: 13%(2/13) for <4µg/ml, 33% (1/3) for 8µg/ml, and 35.2%(6/17) for ≥16µg/ml.[19]   In a 
large cohort study (see Table 4), the mortality rate associated with carbapenem-containing- 
combination therapy for carbapemase-producing K. pneumoniae bacteremia increased from 
19.3% (MIC<8µg/ml) to 35.5% (MIC>8µg/ml).[20].  In a review of 20 clinical studies, 
carbapenem-containing-regimens were associated with lower mortality than non-carbapenem-
containing-regimens (18.8% vs. 30.7%).[12]   While encouraging, it is important to note, that not 
all reports have focused on carbapenem-containing-regimens.  A retrospective study conducted 
from a 10-bed intensive-care-unit (ICU) showed success in 24/26(92%) patients with KPC 
infections (16 ventilator-associated pneumonias [VAP], 7 bloodstream infections, 2 urinary tract 
infections [UTI], 1 peritonitis) with the use of carbapenem-sparing-combination therapy 
regimens.[21] 
 Double-carbapenem combination treatment may be an effective option for infections 
caused by pan-drug-resistant CRE, however data is limited to selected case reports.[22, 23]  
Experimental data has shown that the KPC enzyme may have increased affinity for ertapenem 
than other carbapenems, therefore when given together; KPC preferentially deactivates 
ertapenem, which hinders degradation and improves the activity of the concomitant 
carbapenem.[24, 25]  In case reports, ertapenem plus either doripenem or meropenem has 
been used successfully to treat select pan-drug-resistant and colistin-resistant KPC-producing 
K. pneumoniae infections (bacteremia, VAP, and UTI). Double-carbapenem combination 
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treatment is a promising option, which may be most effective in combination with a third 
drug.[26]  
 
Polymyxins. Colistin (polymyxin E) and polymyxin B are considered to be the most active in 
vitro agents against CRE.[27]  Polymyxin B and colistin differ by a single amino acid.  A 
comparison of the two drugs can be found in Table 5. There are several potential advantages to 
the use of polymyxin B over colistin, many of which stem from the fact that colistin is 
administered as the inactive prodrug colistimethate (CMS).  Only a small fraction of CMS is 
converted to colistin and this conversion is slow, with maximum concentrations occurring >7 
hours after administration.[28]  As the conversion of CMS to colistin is slow and inefficient in 
patients with normal renal function the majority of CMS is cleared prior to conversion to colistin. 
Therefore, despite being dosed at a lower mg/kg/day dose, polymyxin B can achieve higher 
peak serum concentrations which are achieved much more rapidly than with colistin.[28, 29]  
Renal dose adjustments are necessary for colistin/CMS but are not required polymyxin 
B.[26] The reason for this is that there is minimal renal clearance of colistin, but the prodrug 
CMS is predominately cleared renally.[26]  As with colistin, polymyxin B undergoes extensive 
renal tubular reabsorption and is eliminated by mostly nonrenal clearance. Importantly, 
however, polymyxin B package insert dosing recommendations include vague renal dosing 
adjustments that have been followed in all of the polymyxin B literature to date. The efficacy and 
safety of non-renally adjusted polmyxin B remains unclear.  The renal clearance of CMS allows 
an advantage over polymyxin B that a higher concentration of active drug in the urine is reached 
which would make colistin/CMS a viable UTI treatment alternative.[26, 30]  Despite the potential 
advantages of polymyxin B use, the majority of clinical data to date for CRE infections has 
focused on the use of colistin. 
 The ideal dosages of colistin and polymyxin B are largely unknown, especially in the 
case of renal failure, renal replacement therapy, and critical illness.[31] Scientifically based 
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dosing recommendations can be found in Table 5.[28, 29]  For serious infections caused by 
resistant Gram-negative pathogens, high total daily doses of colistin appear to be important to 
maximize treatment efficacy.[28, 32]  In a retrospective study of 258 ICU patients treated with 
CMS, 21.7% of patients on the highest total daily dose (9 million IU/day) died as compared to 
27.8% and 38.6% patients on lower doses of 6 and 3 million IU/day, respectively 
(p=0.0011).[33]   In a retrospective study of 67 patients with Gram-negative bacteremia, the 
median colistin dose was higher in patients who achieved microbiological success (2.9 vs. 
1.5mg/kg/day; P=0.011) and 7-day survival (2.7 vs 1.5mg/kg/day; P=0.007).[32] Another 
retrospective study found similar results with polymyxin B treatment.[34]  
 Historically, neurotoxicity was an important concern with the use of polymyxins, however 
with current formulations this side effect is reported less frequently.  Patients discussed in the 
recent literature are more critically ill, ventilated, and sedated which might significantly limit the 
ability to detect neurotoxicity, which primarily manifested as parasthesias and ataxia. However, 
nephrotoxicity remains a concern as it continues to occur in >40% patients treated with 
polymyxins.[35]   While nephrotoxicity has been reported with both colistin and polymyxin B use, 
recent evidence suggests that nephrotoxicity rates might be higher with colistin use than 
polymyxin B (50-60% vs. 20-40%).[35, 36]  The use of colistin and polymyxin B at higher doses, 
which may be necessary for CRE infections, may be associated with a higher risk of 
nephrotoxicity.[32, 34]  The better outcomes associated with high dose colistin, may come at the 
cost of worsening renal function.[32]  In a retrospective study, a colistin dose of >5mg/kg of 
ideal body weight/day was independently predictive of the development of renal 
insufficiency.[37]  For polymyxin B, a retrospective cohort study of 276 patients demonstrated 
that high doses (>200mg/day) were independently associated with lower mortality (adjusted OR 
0.43; 95% CI 0.23–0.79).[34]  However, the use of ≥200mg/day was associated with a 
significantly higher risk of severe renal impairment (adjusted OR 4.51; 95% CI 1.58–12.90; 
P = 0.005).  Even when controlling for the development of moderate to severe renal 
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dysfunction, multivariate analyses showed that doses ≥200mg/day were still associated with 
decreases in mortality. 
 Another concern with the use of polymyxins is on-treatment resistance development. 
Blood isolates from one patient infected with carbapenem-resistant K. pneumoniae and treated 
with polymyxin B monotheray, showed a significantly increased polymyxin B MIC in just 5 days 
(0.75µg/ml to 1,024µg/ml).[9] Additionally, there have been reports of colistin-resistant, 
carbapenem-resistant K. pneumoniae outbreaks.[38, 39]  Therefore, polymyxins may be most 
effective as part of a combination for serious CRE infections.[31, 40]  In a recent review which 
used compiled data on 889 patients with CRE infections (bacteremia, pneumonia, intra-
abdominal infections, UTIs, and surgical site infections), the mortality rate for colistin 
monotherapy was 42.8%.[12]   A review of 55 studies found that clinical success was lower for 
colistin monotherapy as compared to colistin combination therapy for treatment of infections 
caused by KPC-producers (14% [1/7] vs. 73% [8/11]).[41]  In a recent cohort study of 36 
patients with blood stream infections due to CRE (all but two yielded both OXA-48 and CTX-M 
ESBLs), colistin based combination therapy was associated with better 28-day survival than 
non-colistin regimens (33.3% vs. 5.5%; p=0.018).[42]  
 
Tigecycline. The majority of CRE isolates remain active against tigecyline in vitro, however 
resistance to tigecycline is increasing.[43-45]  There are only limited clinical data to support use 
of tigecycline monotherapy for infections caused by CRE that demonstrate in vitro 
susceptibility.[19, 20, 41, 46, 47]  In a small number of patients with carbapenem-resistant K. 
pneumoniae, 71.4% (5/7) patients had a favorable outcome with tigecycline treatment.[41]  High 
mortality rates have been reported with the use of tigecycline monotherapy in the treatment of 
bloodstream infections due to carbapenem-resistant K. pneumoniae in two separate cohort 
studies (see Table 4).[19, 20]   Additionally, despite in vitro susceptibility, on-treatment 
resistance emergence has been described.[10, 40, 48] 
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Tigecycline may be most effective when used at higher doses and/or in combination for 
serious CRE infections, and depending on the source of the infection.[40, 49, 50]  However, 
high dose tigecycline may only transiently lead to increased plasma concentrations, as higher 
doses may lead to increased intracellular accumulation and tissue distribution.[49] In 30 
complex patients with severe intra-abdominal infections due to KPC-producing K. pneumoniae, 
high dose tigecycline in combination with colistin was associated with lower mortality as 
compared to approved dose tigecycline plus colistin.[51] In a review which used compiled data 
on patients with various types of CRE infections, the mortality rate with tigecycline monotherapy 
was 41.1%.[12]  A carbapenem-sparing regimen of tigecycline plus either gentamicin or colistin 
was effective in 92%(24/26) of ICU patients treated for KPC infections.[21]  
 
Fosfomycin. Limited data has demonstrated fosfomycin has activity against KPC-producing K. 
pneumoniae and NDM-1-producing enterobacteriaceae.[52, 53]  Fosfomycin achieves high 
urinary concentrations for prolonged time periods (after a single 3 gram dose peak urine 
concentrations of >4000µg/ml are obtained and above MIC concentrations persist for 72 
hours).[54]  Select case reports have demonstrated success of oral fosfomycin for treating UTIs 
caused by fosfomycin susceptible KPC- and NDM-producing enterobacteriaceae.[55, 56]  Two 
patients with OXA-48-producing K. pneumoniae UTIs were successfully treated with oral 
fosfomycin and colistin.[57] 
In Europe an intravenous fosfomycin formulation is available.  In a small (n=11) 
European study, intravenous fosfomycin (2-4 g q6h) in combination was associated with good 
bacteriological and clinical outcomes in all patients for various carbapenem-resistant K. 
pneumoniae infections (bacteremia, VAP, UTI, wound infections).[58]  In a report of three cases 
of KPC-producing K. pneumoniae bacteremia, intravenous fosfomycin was used as an adjunct 
“last-resort” treatment which initially led to bacteremia control, however ultimately all three 
patients failed treatment due to relapse and resistance development.[59]  The use of 
  11
intravenous fosfomycin monotherapy for the treatment of systemic infections may be limited due 
to the potential for the development of drug resistance during treatment.[60] 
 
Aminoglycosides.  Gentamicin is generally the most active aminoglycoside in vitro against 
carbapenem-resistant K. pneumoniae, however amikacin can be most active against other 
CRE.[46, 61, 62] Data on the use of aminoglycosides as monotherapy is limited and 
aminoglycosides monotherapy appears to be most efficacious in the treatment of UTIs.[12, 41, 
63]  In a retrospective cohort study of cases of carbapenem-resistant K. pneumoniae 
bacteriuria, treatment with an in vitro active aminoglycoside was associated with a significantly 
higher rate of microbiologic clearance as compared to either polymyxin B or tigecycline.[63]  In 
multivariate analysis, aminoglycoside treatment was independently associated with 
microbiologic clearance.   
Aminoglycoside therapy may be most appropriate as a component of combination 
therapy for infections, especially UTIs, caused by CRE.[64-66]  In the largest CRE bacteremia 
cohort study to date, similar mortality rates were observed for aminoglycoside monotherapy 
(22.2%) and combination therapy (26.5%), however only a small number of patients (n=9) were 
treated with monotherapy as compared to 68 patients treated with aminoglycoside combination 
therapy.[20] In a review of 24 cases of aminoglycoside combination therapy (most often with 
colistin, carbapenems, fluoroquinolones, and tigecycline), all patients who failed aminoglycoside 
based combination therapy had bloodstream infections.[66]  In a review of 20 clinical studies, 
the combination of an aminoglycoside and a carbapenem had the lowest mortality rate 
(11.1%).[12]  
 
Combination Therapy. Combination therapy for CRE infections may decrease mortality as 
compared to monotherapy.  It is also an important empiric consideration when a CRE is 
suspected.[18, 19, 31]  Benefits of combination therapy include reduction of initial inappropriate 
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antimicrobial therapy, potential synergistic effects, and suppression of emerging resistance.[31] 
As monotherapy options all have significant limitations (pharmacokinetics, toxicity, emergence 
of resistance), combination therapy can be an attractive option to optimize therapy.  However, 
with combination therapy there is the potential for an increased risk for the development of 
Clostridium difficile infection, colonization/infection with other resistant bacteria, and adverse 
effects such as nephrotoxicity.[11, 31]  Combination therapy leads to increased antimicrobial 
pressure and may potentiate the development of antimicrobial resistance. The benefits of 
combination therapy may outweigh the risks, and many experts recommend combination 
therapy as opposed to monotherapy for the treatment of severe CRE infections.[31, 40] 
 As previously described, emerging clinical evidence suggests that treatment with 
combination therapy may be beneficial for serious CRE infections.[12, 18-21, 41, 42, 67-69]  In 
the most comprehensive review to date, which included data on 889 patients with CRE 
infections, combination therapy with two or more in vitro active agents was associated with 
lower mortality than treatment with a single in vitro active agent (27.4%[121/441] vs. 
38.7%[134/346], p<0.001).[12]  Monotherapy resulted in mortality rates that were not 
significantly different from those in patients treated with inappropriate therapy with no in vitro 
active agents (46.1%[48/102]).  Another comprehensive review found similar mortality results 
(18.3% vs. 49.1%).[31]  Several observational studies have assessed the efficacy of 
combination therapy versus monotherapy in the treatment of bloodstream infections due to 
carbapenemase-producing K. pneumoniae (mostly KPC-producers).[18-20, 67]  A summary of 
these studies can be found in Table 4. In the first study, all patients who received combination 
therapy had favorable outcomes, while 46.7% patients who received active monotherapy 
died.[67]  The next retrospective cohort study also demonstrated  lower mortality rate with 
combination treatment (usually a carbapenem with colistin or tigecycline) compared with 
monotherapy.[18] A larger multi-center retrospective cohort study also found similar results.[19] 
Interestingly, meropenem, colistin, tigecycline combination was associated with a significant 
  13
reduction in mortality even in patients who received inappropriate empiric therapy (14% vs. 
61%).  In the most recent and largest cohort study to date, combination therapy again was 
associated with lower mortality than monotherapy (27.2% vs. 44.4%).[20]  Combination therapy 
was an independent predictor of survival; which was mostly due to the effectiveness of 
carbapenem-containing regimens.   
 
Emerging treatment.  An overview of emerging treatment options can be found in Table 6.  
The Food and Drug Administration approved ceftazidime-avibactam in February 2015 for the 
treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract 
infections (cUTI).[70]  It is expected that ceftazidime-avibactam will be available in the second 
quarter of 2015, however ceftazidime-avibactam received a priority review based on Phase II 
data, and as such should be reserved for patients with limited or no alternative treatment 
options.[70] 
Ceftazidime-avibactam is combination of an established broad-spectrum cephalosporin 
(ceftazidime) and a novel β-lactamase inhibitor (avibactam) with activity against class A, class 
C, and some class D β-lactamases.[71, 72]  Avibactam has activity against KPC-type 
carbapenemases and some OXA enzymes, however it has no activity against metallo- β -
lactamases (such as NDM-1).[71, 72]  In two Phase II trials, efficacy and safety rates were 
similar for ceftazidime-avibactam versus comparator drugs for the treatment of cIAI and 
cUTI.[73, 74]    For cIAI, favorable clinical response rates were observed for ceftazidime-
avibactam (2000/500 mg IV q8h) plus metronidazole (500 mg IV q8h) as compared to 
meropenem (1000 mg IV q8h; 91.2% [62/68] vs. 93.4% [71/76], p=0.06).[74]  For cUTI, 
favorable clinical response rates were observed for ceftazidime-avibactam (500/125 mg IV q8h) 
as compared to imipenem (500 mg IV q6h; 85.7% [24/28] vs. 80.6% [29/36], p=0.06).[73]  The 
most common adverse drug reactions (>10%) in trials were vomiting, nausea, constipation, and 
anxiety.[70]  In a Phase III trial, clinical cure rates for ceftazidime-avibactam were lower for 
  14
patients with a creatinine clearance between 30 to 50 ml/min.[70]  Additionally, seizures have 
been reported with the use of ceftazidime and as with other β-lactam antibiotics there is a risk 
for serious hypersensitivity.[70]  Phase III trails are underway assessing ceftazidime-avibactam 
for the treatment of cIAI, cUTI, and nosocomial pneumonia and results will likely be available in 
late 2015.[70] 
 
Conclusions. The burden of antimicrobial resistance among Gram-negative pathogens, 
particularly carbapenem-resistant enterobacteriaceae is increasing rapidly worldwide.  
Treatment options for serious CRE infections remains extremely limited at this time.  
Optimization of dosing of currently available agents and combination therapy may be the most 
appropriate treatment strategies at this time.  However, continued research is desperately 
needed, in particular randomized controlled trials, to determine the most appropriate treatment 
for serious CRE infections. 
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